Relative Adrenocortical Insufficiency Following Radioactive Iodine Therapy for Graves’ Disease: A Report of Two Cases

References

• Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med. 2006;354(26):2783–2793. doi:10.1056/NEJMoa054022
   PubMed Web of Science ®Google Scholar
• Ningyi J, et al. Guidelines for radioactive iodine therapy for graves’ hyperthyroidism. Chin J Endocrinol Metabol. 2013;29(6):448–459.
   Google Scholar
• Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421. doi:10.1089/thy.2016.0229
   PubMed Web of Science ®Google Scholar
• Hoshiro M, Ohno Y, Masaki H, et al. Comprehensive study of urinary cortisol metabolites in hyperthyroid and hypothyroid patients. Clin Endocrinol (Oxf). 2006;64(1):37–45. doi:10.1111/j.1365-2265.2005.02412.x
   PubMed Web of Science ®Google Scholar
• Gallagher TF, Hellman L, Finkelstein J, et al. Hyperthyroidism and cortisol secretion in man. J Clin Endocrinol Metabol. 1972;34(6):919. doi:10.1210/jcem-34-6-919
   PubMed Web of Science ®Google Scholar
• Fredette ME, Topor LS. Graves’ thyrotoxicosis leading to adrenal decompensation and hyperandrogenemia in a pediatric patient with salt-wasting congenital adrenal hyperplasia. Case Rep Endocrinol. 2018;2018:2359205.
   PubMed Web of Science ®Google Scholar
• Attaye I, van Andel M, Kooter AJ. More, less or both? BMJ Case Rep. 2018;2018. doi:10.1136/bcr-2017-222355
   PubMedGoogle Scholar
• Skamagas M, Geer E. Autoimmune hyperthyroidism due to secondary adrenal insufficiency: resolution with glucocorticoids. Endocrine Pract. 2011;17(1):85–90. doi:10.4158/EP10069.CR
   PubMed Web of Science ®Google Scholar
• Satoh T, Isozaki O, Suzuki A, et al. 2016 guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition). Endocr J. 2016;63(12):1025–1064. doi:10.1507/endocrj.EJ16-0336
   PubMed Web of Science ®Google Scholar
• Naik D, Jebasingh KF, Thomas N. Delayed diagnosis of Graves’ thyrotoxicosis presenting as recurrent adrenal crisis in primary adrenal insufficiency. J Clin Diagn Res. 2016;10(4):OD20–2. doi:10.7860/JCDR/2016/16395.7678
   PubMedGoogle Scholar
• Bernet VJ. Thyroid hormone misuse and abuse. Endocrine. 2019;66(1):79–86. doi:10.1007/s12020-019-02045-1
   PubMed Web of Science ®Google Scholar
• Karl M, Onumah BM, Cole J, et al. Hypocortisolemia in Graves hyperthyroidism. Endocrine Pract off J Am College Endocrinol Am Assoc Clin Endocrinol. 2009;15(3):220. doi:10.4158/EP.15.3.220
   Web of Science ®Google Scholar
• Agbaht K, Gullu S. Adrenocortical reserves in hyperthyroidism. Endocrine. 2014;45(1):136–143. doi:10.1007/s12020-013-9933-y
   PubMed Web of Science ®Google Scholar
• Price SA, Thondam S, Bondugulapati LNR, et al. Significant attenuation of stimulated cortisol in early Graves disease without adrenal autoimmunity. Endocrine Pract off J Am College Endocrinol Am Assoc Clin Endocrinol. 2012;18(6):924. doi:10.4158/EP12002.OR
   Web of Science ®Google Scholar
• Johnson EO, Kamilaris TC, Calogero AE, et al. Experimentally-induced hyperthyroidism is associated with activation of the rat hypothalamic–pituitary–adrenal axis. Eur J Endocrinol. 2005;153(1):177–185. doi:10.1530/eje.1.01923
   PubMed Web of Science ®Google Scholar
• Mishra SK, Gupta N, Goswami R. Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 microg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: case-control comparative study. J Clin Endocrinol Metab. 2007;92(5):1693–1696. doi:10.1210/jc.2006-2090
   PubMed Web of Science ®Google Scholar
• Tsatsoulis A, Johnson EO, Kalogera CH, et al. The effect of thyrotoxicosis on adrenocortical reserve. Eur J Endocrinol. 2000;142(3):231. doi:10.1530/eje.0.1420231
   PubMed Web of Science ®Google Scholar
• Satoh M, Aso K, Ikehara S, et al. A 3-year-old girl with Graves’ disease with hypoglycemia following transient adrenal hyporesponsiveness. J Pediatr Endocrinol Metab. 2011;24(11–12):1047–1050. doi:10.1515/JPEM.2011.307
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Ragusa F, et al. Th1 chemokines in autoimmune endocrine disorders. J Clin Endocrinol Metab. 2020;105(4):1046–1060. doi:10.1210/clinem/dgz289
   Web of Science ®Google Scholar
• Weetman A. Autoimmune thyroid disease. Endocrine. 2020;68(2):258–260. doi:10.1007/s12020-020-02188-6
   PubMed Web of Science ®Google Scholar
• Kim M, Kim BH, Jang MH, et al. High neutrophil-to-lymphocyte ratio is associated with relapse in Graves’ disease after antithyroid drug therapy. Endocrine. 2020;67(2):406–411. doi:10.1007/s12020-019-02137-y
   PubMed Web of Science ®Google Scholar
• Mizokami T, Hamada K, Maruta T, et al. Painful radiation thyroiditis after 131I therapy for graves‘ hyperthyroidism: clinical features and ultrasonographic findings in five cases. Eur Thyroid J. 2016;5(3):201–206. doi:10.1159/000448398
   PubMed Web of Science ®Google Scholar
• Happel C, Kranert WT, Gröner D, et al. Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of 131I during radioiodine therapy of Graves’ disease. Endocrine. 2021. doi:10.1007/s12020-020-02593-x
   PubMed Web of Science ®Google Scholar
• Halstenberg J, Kranert WT, Korkusuz H, et al. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves’ disease]. Nuklearmedizin. 2018;57(2):43–49. German. doi:10.3413/Nukmed-0941-17-11
   PubMedGoogle Scholar
• Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33(6):920–980.
   PubMed Web of Science ®Google Scholar
• Vennard K, Gilbert MP. Thyroid storm and complete heart block after treatment with radioactive iodine. Case Rep Endocrinol. 2018;2018:8214169. doi:10.1155/2018/8214169
   PubMed Web of Science ®Google Scholar
• Nascif SO, Molica P, Correa-Silva SR, et al. Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis. Pituitary. 2009;12(4):315–321. doi:10.1007/s11102-009-0181-3
   PubMed Web of Science ®Google Scholar
• Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med. 2017;43(12):1751–1763. doi:10.1007/s00134-017-4919-5
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves‘ Orbitopathy Guidelines for the Management of Graves‘ Orbitopathy. Eur Thyroid J. 2016;5(1):9–26. doi:10.1159/000443828
   PubMed Web of Science ®Google Scholar